(2-Pack) IPAMORELIN – 10mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Ipamorelin, the First Selective Growth Hormone Secretagogue
European Journal of Endocrinology
Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.
Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers
Pharmaceutical Research
Dose-escalation trial demonstrated ipamorelin produces a GH release episode peaking at 0.67 hours with terminal half-life of 2 hours across five dose levels in healthy male volunteers.
Ipamorelin Induces Longitudinal Bone Growth in Rats
Growth Hormone & IGF Research
Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced dose-dependent effects on body weight gain in adult female rats.
Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Growth Hormone Release via Hypothalamic GHS-R1a in Conscious Rats
Growth Hormone & IGF Research
Ipamorelin demonstrated potent, dose-dependent GH release without affecting ACTH, cortisol, prolactin, FSH, LH, or TSH — establishing it as the most selective growth hormone secretagogue known.
The GH Secretagogue Ipamorelin Counteracts Glucocorticoid-Induced Decrease in Bone Formation of Adult Rats
Growth Hormone & IGF Research
Ipamorelin prevented dexamethasone-induced bone loss in adult rats, maintaining bone formation markers and trabecular bone mineral density through sustained GH/IGF-I axis stimulation.
Acceleration of Postoperative Bowel Recovery by Ipamorelin: A Novel Growth Hormone Secretagogue
Neurogastroenterology & Motility
Phase II trial in patients after abdominal surgery demonstrated ipamorelin significantly accelerated time to first bowel movement and hospital discharge, acting through ghrelin receptor-mediated prokinetic effects.